Disease · MONDO_0006810

intracranial hypertension

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. intracranial hypertension. Diseases, record MONDO_0006810. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006810

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: intracranial hypertension; Open Targets
Open Targets ID: MONDO_0006810; Open Targets
Other names: Increased intracranial pressure, Intracranial pressure elevation, Raised intracranial pressure, Rise in pressure inside skull; Open Targets
Disease Ontology: DOID:9428; Disease Ontology
MeSH: D019586; MeSH
Highest stage of its drugs: Phase 3, for 5 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 3	ClinicalTrials.gov	11	11	4	Drugs and targets
MANNITOL	CHEMBL689	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
SODIUM LACTATE	CHEMBL1357	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PENTOBARBITAL	CHEMBL448	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
THIOPENTAL	CHEMBL441	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SEVOFLURANE	CHEMBL1200694	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FOSAPREPITANT	CHEMBL1199324	Small molecule	Early phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ACETAZOLAMIDE	CHEMBL20	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
KETAMINE	CHEMBL742	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
PROPOFOL	CHEMBL526	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GABRA1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2561	Drugs and targets
GABRB3	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2562	Drugs and targets
GABRD	GABA-A receptor; anion channel	4	GABA-A receptor; anion channel positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/2563	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials19

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03276494	Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access	Phase 2	6	2019-07-09	Stroke, Intracranial Hypotension, Cerebral Edema	SODIUM CHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT03143751	Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients	Phase 3	370		Moderate to Severe Traumatic Brain Injury	SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT06945848	Venous Stenting Evaluation in Patients With Intracranial Hypertension Under Long-term Acetazolamide	Not applicable	114		Idiopathic Intracranial Hypertension (IIH)	ACETAZOLAMIDE	Its record names the disease	ClinicalTrials.gov
NCT03444519	The Therapeutic Time Window of Mannitol During Craniotomy for Optimal Brain Relaxation in Patients With Supratentorial Tumours	Not applicable	100		Supratentorial Tumors	MANNITOL	Its record names the disease	ClinicalTrials.gov
NCT04415905	Comparison of Optic Nerve Sheath Diameter in Children Receiving Caudal Block According to Anesthetic Agents: Total Intravenous Anesthesia vs. Volatile Anesthesia	Not applicable	60		Caudal Block for Postoperative Analgesia	PROPOFOL, ROPIVACAINE, SEVOFLURANE	Its record names the disease	ClinicalTrials.gov
NCT02460510	Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF	Not applicable	52		Acute Liver Failure	MANNITOL	Its record names the disease	ClinicalTrials.gov
NCT06110429	Sodium Lactate Versus Hypertonic Saline Solution in the Treatment of Intracranial Hypertensive Episodes in Severe Brain Injured Patients	Phase 3	52		Intra Cerebral Hypertension, Lactate Sodium Solution	SODIUM LACTATE	Its record names the disease	ClinicalTrials.gov
NCT00359697	Comparison of Two Different Medications Used to Treat Elevated Intracranial Pressure	Phase 1	50		Increased Intracranial Pressure	MANNITOL	Its record names the disease	ClinicalTrials.gov
NCT00622570	Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension	Phase 3	44		Traumatic Brain Injury	PENTOBARBITAL, THIOPENTAL	Its record names the disease	ClinicalTrials.gov
NCT00319345	Sodium-Lactate and Traumatic Brain Injury	Phase 2/3	34		Severe Trauma Brain Injury, Intracranial Hypertension	MANNITOL, SODIUM LACTATE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 19

See all 19 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials5

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
15756405	RESULT	1	PubMed
36707841	DERIVED	1	PubMed
34032829	DERIVED	1	PubMed
28947465	DERIVED	1	PubMed
18759980	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006810

GET https://conductscience.org/api/diseases/v1/MONDO_0006810/targets?page=2

API reference For AI assistants